Celgene Co. (NASDAQ:CELG) had its price objective trimmed by Barclays from $130.00 to $120.00 in a report issued on Saturday morning, StockTargetPrices.com reports. The brokerage currently has an equal weight rating on the biopharmaceutical company’s stock.

Celgene (NASDAQ:CELG) opened at 100.32 on Friday. The stock has a 50 day moving average price of $110.50 and a 200 day moving average price of $118.19. Celgene has a 52 week low of $92.98 and a 52 week high of $140.72. The firm has a market cap of $78.82 billion and a price-to-earnings ratio of 50.36.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, January 28th. The biopharmaceutical company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.22 by $0.04. The company earned $2.54 billion during the quarter, compared to analysts’ expectations of $2.54 billion. Celgene’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.01 earnings per share. Equities research analysts expect that Celgene will post $5.71 EPS for the current year.

In related news, Director Michael D. Casey sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 23rd. The stock was sold at an average price of $122.11, for a total transaction of $2,442,200.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Ernest Mario sold 40,000 shares of the company’s stock in a transaction that occurred on Monday, December 28th. The shares were sold at an average price of $119.36, for a total value of $4,774,400.00. Following the sale, the director now directly owns 82,449 shares in the company, valued at $9,841,112.64. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors recently modified their holdings of the company. Park National increased its position in shares of Celgene by 41.2% in the fourth quarter. Park National now owns 2,805 shares of the biopharmaceutical company’s stock worth $336,000 after buying an additional 819 shares during the last quarter. Renaissance Investment Group increased its position in shares of Celgene by 3.8% in the fourth quarter. Renaissance Investment Group now owns 38,661 shares of the biopharmaceutical company’s stock worth $4,630,000 after buying an additional 1,405 shares during the last quarter. EQIS Capital Management increased its position in shares of Celgene by 667.7% in the fourth quarter. EQIS Capital Management now owns 32,166 shares of the biopharmaceutical company’s stock worth $3,852,000 after buying an additional 27,976 shares during the last quarter. Bath Savings Trust Company increased its position in shares of Celgene by 1.9% in the fourth quarter. Bath Savings Trust Company now owns 80,117 shares of the biopharmaceutical company’s stock worth $9,595,000 after buying an additional 1,481 shares during the last quarter. Finally, Detwiler Fenton Investment Management bought a new position in shares of Celgene during the fourth quarter worth approximately $469,000.

Several other research firms also recently weighed in on CELG. RBC Capital reaffirmed a buy rating and issued a $150.00 price objective on shares of Celgene in a research note on Thursday, November 5th. Vetr downgraded Celgene from a strong-buy rating to a buy rating and set a $135.66 price objective for the company. in a research note on Monday, October 26th. Zacks Investment Research raised Celgene from a hold rating to a strong-buy rating and set a $141.00 price objective for the company in a research note on Monday, November 2nd. Canaccord Genuity reaffirmed a buy rating and issued a $156.00 price objective on shares of Celgene in a research note on Thursday, December 24th. Finally, Argus reaffirmed a buy rating and issued a $155.00 price objective on shares of Celgene in a research note on Thursday, December 24th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, twenty-three have issued a buy rating and four have issued a strong buy rating to the company. The stock presently has an average rating of Buy and an average price target of $147.86.

Celgene Corporation (NASDAQ:CELG), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

12 Month Chart for NASDAQ:CELG

Stock Target Prices

Receive News & Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related companies with MarketBeat.com's FREE daily email newsletter.